Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHL9V3)

Drug Name

4-chloro-N-(2,5-dichlorophenyl)-3-nitrobenzamide Drug Info

Synonyms

4-chloro-N-(2,5-dichlorophenyl)-3-nitrobenzamide; CHEMBL560605; AC1LEF7J; Oprea1_805046; Oprea1_782408; MolPort-001-927-690; ZINC102805; BDBM50297549; STK201761; AKOS000609413; MCULE-5386572276; 2',4,5'-Trichloro-3-nitrobenzanilide; BAS 00368876; 91822-09-2; ST011043; AG-690/09694020; 4-Chloro-N-(2,5-dichloro-phenyl)-3-nitro-benzamide

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 711259
TTD Drug ID: DMHL9V3

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Bacterial Fatty acid synthetase I (Bact inhA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[2]
Pyrazinamide	DM4IF32	Meningeal tuberculosis		Approved	[3]
Ethionamide	DM8K3EI	Pulmonary tuberculosis	1B10.Z	Approved	[4]
Prothionamide	DMX0EZJ	Tuberculosis	1B10-1B1Z	Approved	[4]
AFN-1720	DM6AJKC	Bacterial infection	1A00-1C4Z	Phase 2	[5]
MMV00/0053	DMF27BS	Malaria	1F40-1F45	Terminated	[6]
Nicotinamide-Adenine-Dinucleotide	DM9LRKB	N. A.	N. A.	Investigative	[7]
Beta-D-Glucose	DM5IHYP	Discovery agent	N.A.	Investigative	[7]
2-Hexadecynoic acid	DMTFIPZ	Discovery agent	N.A.	Investigative	[8]
4-(2-Thienyl)-1-(4-Methylbenzyl)-1h-Imidazole	DMX681M	Discovery agent	N.A.	Investigative	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial Fatty acid synthetase I (Bact inhA)	TTVTX4N	INHA_MYCTU	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening. Eur J Med Chem. 2009 Sep;44(9):3718-30.
2	Diversity in enoyl-acyl carrier protein reductases. Cell Mol Life Sci. 2009 May;66(9):1507-17.
3	Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat Med. 2000 Sep;6(9):1043-7.
4	Mechanism of thioamide drug action against tuberculosis and leprosy. J Exp Med. 2007 Jan 22;204(1):73-8.
5	Affinium Pharmaceuticals Announces the Initiation of a Phase 1 Intravenous Clinical Trial of a New Antibiotic Prodrug, and the Closing of a Follow-on Financing Round. PR Newswire Sep. 4, 2013 10:16 PM.
6	SAR and pharmacophore models for the rhodanine inhibitors of Plasmodium falciparum enoyl-acyl carrier protein reductase. IUBMB Life. 2010 Mar;62(3):204-13.
7	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
8	2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections. Bioorg Med Chem. 2010 Nov 1;18(21):7475-85.